To the best of our knowledge, this is the first study to analyze the three datasets collectively, identify the double mutations in CRC, and assess the clinicopathological features, MSI status, and TMB of KRAS/BRAF double-mutant CRC and compare them with KRAS and BRAF single mutation CRC. This evidence concerns the gene KRAS and colorectal carcinoma.